Stocktoria

Kymera Therapeutics, Inc. KYMR

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-08-21

Kymera Therapeutics, Inc. statistics & valuation

Market cap$8.9B
P / B5.6×
Net margin-794.0%
Return on equity-19.7%
FCF margin-597.6%
Return on capital-21.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-1405.80% -134.00% -137.60% -330.60% -187.00% -475.60% -794.00% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-1438.50% -136.10% -138.00% -344.40% -210.60% -555.80% -891.10% 2019202020212022202320242025
Return on equity (%)
-16.10% -21.80% -31.60% -37.20% -26.80% -19.70% 2019202020212022202320242025
Shares outstanding
1.9M 44.5M 51.5M 55.0M 58.4M 75.0M 84.5M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-35.30% -9.40% -16.50% -25.70% -25.50% -22.90% -17.90% 2019202020212022202320242025
Free cash flow margin (%)
592.10% 232.20% -179.20% -333.00% -174.70% -440.50% -597.60% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$3.15 -$2.09 -$2.87 -$2.52 -$2.98 -$3.69 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-891.1%-555.8%-210.6%-344.4%-138.0%-136.1%-1438.5%
Net margin-794.0%-475.6%-187.0%-330.6%-137.6%-134.0%-1405.8%
FCF margin-597.6%-440.5%-174.7%-333.0%-179.2%232.2%592.1%
Return on assets-17.9%-22.9%-25.5%-25.7%-16.5%-9.4%-35.3%
Return on equity-19.7%-26.8%-37.2%-31.6%-21.8%-16.1%55.4%
Current ratio10.477.534.735.884.882.732.69

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.